Reported 12 months ago
President Biden and Senator Bernie Sanders are urging for reductions in the prices of popular GLP-1 weight-loss medications, leading to a drop in pharmaceutical stocks like Novo Nordisk and Eli Lilly. The political discourse involves an op-ed by Biden and Sanders published in USA Today discussing affordability issues with these treatments. This move signals a potential shift in government influence on drug pricing and impacts on the pharmaceutical industry.
Source: YAHOO